JPWO2019165458A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019165458A5 JPWO2019165458A5 JP2020544853A JP2020544853A JPWO2019165458A5 JP WO2019165458 A5 JPWO2019165458 A5 JP WO2019165458A5 JP 2020544853 A JP2020544853 A JP 2020544853A JP 2020544853 A JP2020544853 A JP 2020544853A JP WO2019165458 A5 JPWO2019165458 A5 JP WO2019165458A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- effective amount
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 151
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- -1 SRA737 compound Chemical class 0.000 claims description 61
- 201000011510 cancer Diseases 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 230000037361 pathway Effects 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 101150113535 chek1 gene Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 230000005971 DNA damage repair Effects 0.000 claims description 6
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims description 6
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims description 6
- 230000033607 mismatch repair Effects 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 108700020463 BRCA1 Proteins 0.000 claims description 5
- 102000036365 BRCA1 Human genes 0.000 claims description 5
- 101150072950 BRCA1 gene Proteins 0.000 claims description 5
- 108700020462 BRCA2 Proteins 0.000 claims description 5
- 102000052609 BRCA2 Human genes 0.000 claims description 5
- 101150008921 Brca2 gene Proteins 0.000 claims description 5
- 230000002411 adverse Effects 0.000 claims description 5
- 102000000872 ATM Human genes 0.000 claims description 4
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 230000000711 cancerogenic effect Effects 0.000 claims description 4
- 231100000315 carcinogenic Toxicity 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 101100043112 Homo sapiens SERPINB3 gene Proteins 0.000 claims description 3
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 3
- 102100036383 Serpin B3 Human genes 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 2
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims description 2
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims description 2
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 2
- 102100030708 GTPase KRas Human genes 0.000 claims description 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims description 2
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims description 2
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 2
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 2
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000046961 MRE11 Homologue Human genes 0.000 claims description 2
- 108700019589 MRE11 Homologue Proteins 0.000 claims description 2
- 108700012912 MYCN Proteins 0.000 claims description 2
- 101150022024 MYCN gene Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims description 2
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 101150071637 mre11 gene Proteins 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 2
- 229950011068 niraparib Drugs 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 238000005259 measurement Methods 0.000 description 7
- 206010044412 transitional cell carcinoma Diseases 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010073135 Dedifferentiated liposarcoma Diseases 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 208000032249 Squamous cell carcinoma of the penis Diseases 0.000 description 1
- 206010041866 Squamous cell carcinoma of the vagina Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000000270 spindle cell sarcoma Diseases 0.000 description 1
- 208000021333 squamous cell carcinoma of penis Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000021153 vaginal squamous cell carcinoma Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023195862A JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635459P | 2018-02-26 | 2018-02-26 | |
| US62/635,459 | 2018-02-26 | ||
| US201862650192P | 2018-03-29 | 2018-03-29 | |
| US62/650,192 | 2018-03-29 | ||
| US201862743993P | 2018-10-10 | 2018-10-10 | |
| US62/743,993 | 2018-10-10 | ||
| PCT/US2019/019643 WO2019165458A1 (en) | 2018-02-26 | 2019-02-26 | Methods of treatment of cancer comprising chk1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195862A Division JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514979A JP2021514979A (ja) | 2021-06-17 |
| JPWO2019165458A5 true JPWO2019165458A5 (https=) | 2022-03-04 |
| JP2021514979A5 JP2021514979A5 (https=) | 2022-03-04 |
Family
ID=67687903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544853A Withdrawn JP2021514979A (ja) | 2018-02-26 | 2019-02-26 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
| JP2023195862A Pending JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195862A Pending JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200397796A1 (https=) |
| EP (1) | EP3758678A4 (https=) |
| JP (2) | JP2021514979A (https=) |
| KR (1) | KR20200126388A (https=) |
| CN (1) | CN112469391A (https=) |
| AU (1) | AU2019224164A1 (https=) |
| CA (1) | CA3092079A1 (https=) |
| MX (1) | MX2020008881A (https=) |
| WO (1) | WO2019165458A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3609884A4 (en) | 2017-04-10 | 2021-01-06 | Sierra Oncology, Inc. | CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH |
| US20220226338A1 (en) * | 2019-05-14 | 2022-07-21 | Sierra Oncology, Inc. | Methods of Treating Cancer Using CHK1 Inhibitors |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| AU2021325905A1 (en) * | 2020-08-12 | 2023-04-13 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| EP2755482B1 (en) * | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
| RU2659786C2 (ru) * | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
| EP3609884A4 (en) * | 2017-04-10 | 2021-01-06 | Sierra Oncology, Inc. | CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH |
| CA3065803A1 (en) * | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
-
2019
- 2019-02-26 CA CA3092079A patent/CA3092079A1/en active Pending
- 2019-02-26 US US16/975,686 patent/US20200397796A1/en not_active Abandoned
- 2019-02-26 MX MX2020008881A patent/MX2020008881A/es unknown
- 2019-02-26 CN CN201980018748.5A patent/CN112469391A/zh active Pending
- 2019-02-26 JP JP2020544853A patent/JP2021514979A/ja not_active Withdrawn
- 2019-02-26 EP EP19757456.9A patent/EP3758678A4/en not_active Withdrawn
- 2019-02-26 WO PCT/US2019/019643 patent/WO2019165458A1/en not_active Ceased
- 2019-02-26 KR KR1020207026214A patent/KR20200126388A/ko not_active Ceased
- 2019-02-26 AU AU2019224164A patent/AU2019224164A1/en not_active Abandoned
-
2023
- 2023-11-17 JP JP2023195862A patent/JP2024012649A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| JP2024081770A (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート | |
| JP2021514979A5 (https=) | ||
| JP2022087185A5 (https=) | ||
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| JPWO2019230645A1 (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 | |
| CN116194110A (zh) | 用于治疗癌症的组合疗法 | |
| GEAP202416383A (en) | Use of medicament in treatment of tumor disease | |
| Zhu et al. | Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer | |
| JPWO2019160829A5 (https=) | ||
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| CN117956998A (zh) | 治疗kras突变的癌症患者 | |
| WO2023095929A1 (ja) | 悪性腫瘍治療薬 | |
| CN114028579B (zh) | 核酸适配体-药物结合物PTK7-GEMs在制备治疗膀胱癌药物中的应用 | |
| JPWO2019165458A5 (https=) | ||
| JPWO2019160751A5 (https=) | ||
| JP2023542065A (ja) | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ | |
| Ichikawa et al. | Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository | |
| CN112741833A (zh) | 西达本胺及其衍生物的用途 | |
| US20210187072A1 (en) | Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemia | |
| Li et al. | 3H-3000, an FGFR2B-specific monoclonal antibody, shows superior tumor killing in vivo | |
| JP2025513929A5 (https=) | ||
| JPWO2021161262A5 (https=) | ||
| TW201803566A (zh) | 用於癌症治療之維持療法 | |
| US20220323443A1 (en) | Combination therapy for cancer treatment |